TORS for head and neck squamous cell carcinoma (HNSCC): the Hamburg experience.

CONCLUSION: Using TORS as their primary modality, 40% of the patients did not need adjuvant treatment and showed similar survival rates to that of conventional surgery or primary chemoradiotherapy. In another 34% of the patients, adjuvant chemotherapy could be spared and adjuvant radiotherapy could be reduced by 10 Gy, compared to primary chemoradiotherapy of 70 Gy. This invited report is based on previously published data by the same authors. PMID: 26891529 [PubMed - in process]
Source: B-ENT - Category: ENT & OMF Tags: B-ENT Source Type: research